Latest New Zealand News

Critical Resources Limited has secured $1.6 million through a share placement to fund exploration across multiple jurisdictions and advance early-stage battery and thermal management technologies.

EMVision has accelerated recruitment in its pivotal emu™ brain scanner trial, surpassing 200 patients and advancing FDA discussions to broaden clinical endpoints, setting the stage for regulatory submission in early 2027.

PeopleIN Limited reversed its earnings decline in FY26, driven by a 74.8% surge in its Engineering, Trades and Labour division amid Queensland’s booming infrastructure projects. The company’s sharper portfolio focus and strengthened balance sheet set the stage for further growth.

AVADA Group lifted revenue by nearly 15% in FY26, driven by Queensland and New South Wales expansion, while managing a $15 million impairment in Victoria that kept the statutory loss steady.

Michael Hill International delivered a landmark FY26 with record revenue of AU$655.7 million, a 57% jump in comparable EBIT, and reinstated dividends after a strategic turnaround.

Enprise Group reported a $2.2 million net loss for FY2026 amid rising revenue and cost pressures, prompting a strategic reset aimed at returning to profitability in FY2027.

Michael Hill International reported a 1.9% revenue increase to $655.7 million in FY26, with comparable EBIT up 57% to $24 million and net profit soaring 376%. The company restored dividends and announced a Chair succession.

OMG Group posted a 48% revenue increase to $6.13 million in FY26, achieving its highest-ever gross margin of 41% while expanding distribution into New Zealand and Southeast Asia.

Jatcorp Limited's FY26 results show a 23% revenue increase to $38.9 million but a 41% larger loss attributable to owners. The company faces a material uncertainty over going concern despite improved statutory NPAT.

BHP Group has updated its dividend announcement with South African Rand currency details and confirmed a fully franked USD 0.99 dividend for the six months ending June 2026. Shareholders can elect to receive payments in five currencies, with a Dividend Reinvestment Plan available at no discount.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Foresta Group Holdings reports a doubling of its net loss to $6.8 million for FY2026 amid steady progress on its Kawerau biomass facility, highlighted by a long-term lease and key technical studies.